Antoine Jakiche, MD
Gastroenterology · Albuquerque, NMNPI 1609875996
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $83,145 of the $107,810 with a category attached, or 77.1%. Gilead accounts for 61.3% of it on its own, with 33 other manufacturers making up the rest. 2025 is the largest year on record at $37,484, 2.9 times the $13,065 reported in 2019. Among gastroenterology clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 284 payments — averaging $379.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$66K
- Madrigal Pharmaceuticals$37K
- AbbVie$1K
- Johnson & Johnson$592
- Pfizer$332
- Boston Scientific$304
- plus $2K from 28 others
Across 296 payments — averaging $2836.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$314K
- Intercept Pharmaceuticals, Inc.$244K
- Novartis$147K
- Ipsen Bioscience Inc.$100K
- Intercept Pharma Europe Ltd.$25K
- Gilead$8K
- plus $934 from 1 others
What the payments were for
- Consulting fees$5,2885%
- Speaking & faculty fees$83,14577%
- Travel & lodging$10,82110%
- Food & beverage$8,3618%
- Education$1960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 87 | $66,062 |
| Madrigal Pharmaceuticals | 34 | $37,322 |
| AbbVie | 57 | $1,011 |
| Johnson & Johnson | 21 | $592 |
| Pfizer | 11 | $332 |
| Boston Scientific | 4 | $304 |
| Intuitive Surgical | 1 | $270 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $238 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $232 |
| Novo Nordisk | 2 | $223 |
| Ipsen Biopharmaceuticals, Inc | 5 | $196 |
| Aimmune Therapeutics, Inc. | 1 | $125 |
| Bristol Myers Squibb | 7 | $118 |
| Alnylam Pharmaceuticals Inc. | 1 | $112 |
| Phathom Pharmaceuticals, Inc. | 4 | $97 |
| Olympus America Inc. | 4 | $67 |
| Regeneron Healthcare Solutions, Inc. | 3 | $57 |
| Sanofi | 3 | $51 |
| Nestle Healthcare Nutrition Inc. | 3 | $48 |
| Daiichi Sankyo Inc. | 3 | $46 |
| Ardelyx, Inc. | 2 | $40 |
| Organon | 2 | $39 |
| Medtronic | 1 | $33 |
| ERBE USA Inc | 1 | $24 |
| Ambu Inc. | 1 | $23 |
| Biocon Biologics Inc | 1 | $23 |
| AstraZeneca | 1 | $22 |
| QOL Medical, LLC | 1 | $19 |
| Celltrion USA Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
| Mallinckrodt Hospital Products Inc. | 1 | $13 |
| Digestive Care, Inc. | 1 | $13 |
| Merck | 1 | $12 |
| Endogastric Solutions, Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$107,810 in reported general payments places this provider in the 95th percentile of 81 gastroenterology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 41 | $64,653 |
| XifaxanRifaximin | 17 | $55,342 |
| TrulancePlecanatide | 16 | $14,760 |
| ZenpepLipase/Protease/Amylase | 11 | $13,570 |
| Mesalamine | 36 | $11,736 |
| Ursodiol | 78 | $11,693 |
| LinzessLinaclotide | 15 | $10,557 |
| Budesonide DrBudesonide | 25 | $4,208 |
| Esomeprazole Magnesium | 106 | $3,563 |
| Azathioprine | 45 | $3,386 |
| Omeprazole | 189 | $3,234 |
| Famotidine | 121 | $3,138 |
| Balsalazide Disodium | 11 | $2,136 |
| Cholestyramine LightCholestyramine | 14 | $1,647 |
| Sucralfate | 23 | $1,077 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $1,011 | $75,21056 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $238 | $70,10333 claims |
| Aimmune Therapeutics, Inc.Zenpep | $125 | $13,57011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 81 gastroenterology providers in New Mexico.
Other gastroenterology in Albuquerque
- Fazia MirAlbuquerque$98K
- Christopher ChangAlbuquerque$51K
- Stuart WeismanAlbuquerque$19K
- Denis McCarthyAlbuquerque$17K
- Andrei GasicAlbuquerque$9K
- Amal ShineAlbuquerque$7K
- Julie FarrerAlbuquerque$7K
- Zachary NeubertAlbuquerque$5K
- Jessica RyderAlbuquerque$5K
- Athanasios DesalermosAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.